• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    10/5/23 9:10:42 AM ET
    $CMRA
    $DYAI
    $ICU
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CMRA alert in real time by email

    Gainers

    • Dyadic International (NASDAQ:DYAI) shares rose 10.9% to $2.24 during Thursday's pre-market session. The company's market cap stands at $64.5 million.
    • MAIA Biotechnology (AMEX:MAIA) shares increased by 9.93% to $2.44. The market value of their outstanding shares is at $33.3 million.
    • KORU Medical Systems (NASDAQ:KRMD) shares increased by 8.95% to $2.92. The company's market cap stands at $133.2 million.
    • Comera Life Sciences (NASDAQ:CMRA) shares rose 8.57% to $0.3. The company's market cap stands at $9.3 million.
    • Nuwellis (NASDAQ:NUWE) shares rose 8.06% to $1.07. The company's market cap stands at $1.9 million.
    • Xilio Therapeutics (NASDAQ:XLO) shares rose 8.0% to $2.16. The company's market cap stands at $59.4 million.

    Losers

    • MaxCyte (NASDAQ:MXCT) shares decreased by 19.6% to $2.63 during Thursday's pre-market session. The company's market cap stands at $272.2 million.
    • SeaStar Medical Holding (NASDAQ:ICU) shares declined by 11.85% to $0.52. The market value of their outstanding shares is at $10.1 million.
    • Owlet (NYSE:OWLT) shares declined by 11.81% to $3.95. The market value of their outstanding shares is at $33.4 million.
    • Nanobiotix (NASDAQ:NBTX) stock declined by 11.02% to $8.0. The company's market cap stands at $278.8 million.
    • Innate Pharma (NASDAQ:IPHA) stock declined by 10.94% to $2.2. The company's market cap stands at $177.0 million.
    • Neoleukin Therapeutics (NASDAQ:NLTX) stock declined by 10.82% to $3.57. The market value of their outstanding shares is at $31.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CMRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CMRA
    $DYAI
    $ICU
    $IPHA

    CompanyDatePrice TargetRatingAnalyst
    Nanobiotix S.A.
    $NBTX
    2/6/2026Buy
    TD Cowen
    Owlet Inc.
    $OWLT
    12/9/2025Outperform
    William Blair
    Dyadic International Inc.
    $DYAI
    10/23/2025$3.00Buy
    H.C. Wainwright
    Innate Pharma S.A. ADS
    $IPHA
    9/18/2025Buy → Neutral
    H.C. Wainwright
    Innate Pharma S.A. ADS
    $IPHA
    9/18/2025Outperform → Market Perform
    Leerink Partners
    Dyadic International Inc.
    $DYAI
    9/8/2025Buy
    Craig Hallum
    MaxCyte Inc.
    $MXCT
    8/11/2025Buy → Neutral
    BTIG Research
    MaxCyte Inc.
    $MXCT
    8/7/2025Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $CMRA
    $DYAI
    $ICU
    $IPHA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Nanobiotix

    TD Cowen initiated coverage of Nanobiotix with a rating of Buy

    2/6/26 8:11:18 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Owlet

    William Blair initiated coverage of Owlet with a rating of Outperform

    12/9/25 8:52:06 AM ET
    $OWLT
    Industrial Machinery/Components
    Industrials

    H.C. Wainwright resumed coverage on Dyadic International with a new price target

    H.C. Wainwright resumed coverage of Dyadic International with a rating of Buy and set a new price target of $3.00

    10/23/25 7:06:50 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMRA
    $DYAI
    $ICU
    $IPHA
    SEC Filings

    View All

    Nuwellis Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Nuwellis, Inc. (0001506492) (Filer)

    2/26/26 8:49:40 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by Nanobiotix S.A.

    6-K - Nanobiotix S.A. (0001760854) (Filer)

    2/25/26 4:15:03 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

    2/24/26 9:00:53 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMRA
    $DYAI
    $ICU
    $IPHA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Smith Stan bought $9,959 worth of shares (2,700 units at $3.69) and received a gift of 20,000 shares (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    1/12/26 8:44:30 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Smith Stan bought $69,999 worth of shares (57,189 units at $1.22) (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    12/23/25 8:18:50 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Chaouki Steven M bought $49,999 worth of shares (40,849 units at $1.22), increasing direct ownership by 37% to 151,873 units (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    12/23/25 8:16:48 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMRA
    $DYAI
    $ICU
    $IPHA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    KORU Medical Systems to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report fourth quarter and full year 2025 financial results on Thursday, March 12, 2026. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast Details The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for

    2/26/26 4:05:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NANOBIOTIX to Participate in Investor Conferences in March

    PARIS and CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ:NBTX - the "Company"), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in these upcoming conferences in March: TD Cowen's Health Care ConferenceDate: Wednesday, March 4, 2026Location: Boston, MATime of the fireside chat: 11:10am ET / 5:10pm CETPresenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix UBS Biotech Summit Miami Date: Monday, March

    2/25/26 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMRA
    $DYAI
    $ICU
    $IPHA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Gilead Sciences, Inc.

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    2/17/26 5:31:38 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Manko Joseph M. Jr. disposed of 1,520,418 shares and acquired 1,032,347 shares, increasing direct ownership by 56% to 782,547 units (SEC Form 4)

    4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

    2/13/26 4:54:09 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Schultz Carisa

    3 - Nuwellis, Inc. (0001506492) (Issuer)

    2/12/26 4:15:30 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CMRA
    $DYAI
    $ICU
    $IPHA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

    SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

    11/14/24 5:44:28 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SeaStar Medical Holding Corporation

    SC 13G - SeaStar Medical Holding Corp (0001831868) (Subject)

    11/14/24 5:35:52 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

    SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

    11/14/24 4:30:23 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMRA
    $DYAI
    $ICU
    $IPHA
    Financials

    Live finance-specific insights

    View All

    KORU Medical Systems to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report fourth quarter and full year 2025 financial results on Thursday, March 12, 2026. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast Details The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for

    2/26/26 4:05:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

    MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will release financial results for the fourth quarter and full year 2025 on March 10, 2026. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-343-4885 (U.S) or 1-203-518-9851 (international) and using the conference ID: N

    2/24/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026

    ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the fourth quarter and full year 2025 after the U.S. market close on Tuesday, March 24th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call DetailsInvestors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advanc

    2/23/26 4:05:00 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CMRA
    $DYAI
    $ICU
    $IPHA
    Leadership Updates

    Live Leadership Updates

    View All

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints Carisa Schultz as Chief Financial Officer

    MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) a medical technology company focused on advancing precision cardiorenal care, today announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026. Ms. Schultz brings extensive healthcare and public company finance leadership experience, most recently serving as Vice President of Finance at NeueHealth (formerly Bright Health Group), a healthcare company previously listed on the New York Stock Exchange. In that role, she led enterprise finance, treasury, and corporate development activities. During her tenure at NeueHealth, she also held progressive leadership roles including A

    1/30/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Announces Changes to Board of Directors

    MINNEAPOLIS, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced the appointment of Katharyn Field and Mika Grasso to its board of directors, effective January 21, 2026. Ms. Field is the Chief Executive Officer of ISpecimen Inc., where she oversees performance improvement and the redevelopment of the proprietary software platform. Prior to serving as Chief Executive Officer she served as President, Chairman, and as an independent director. She has served as a director of LogProstyle since September 2024, as an Executive Director of Akanda Corporation since Ju

    1/23/26 4:40:27 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care